| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.04. | Ocugen, Inc. - 10-K/A, Annual Report | 20 | SEC Filings | ||
| 29.04. | Ocugen, Inc. - 8-K, Current Report | 18 | SEC Filings | ||
| 16.04. | Ocugen, Inc. - 10-K, Annual Report | 41 | SEC Filings | ||
| 10.04. | Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400-Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication | 275 | GlobeNewswire (Europe) | MALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene... ► Artikel lesen | |
| 08.04. | Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial - First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication | 106 | GlobeNewswire (Europe) | MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene... ► Artikel lesen | |
| 01.04. | Ocugen, Inc. - 8-K, Current Report | 9 | SEC Filings | ||
| 01.04. | Ocugen, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 10 | SEC Filings | ||
| 18.03. | Ocugen, Inc. - 8-K, Current Report | 87 | SEC Filings | ||
| 18.03. | Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer | 218 | GlobeNewswire (Europe) | MALVERN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene... ► Artikel lesen | |
| 13.03. | Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410 | 86 | GlobeNewswire (USA) | ||
| 21.02. | Ocugen, Inc. - 8-K, Current Report | 96 | SEC Filings | ||
| 16.01. | Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board | 42 | GlobeNewswire (USA) | ||
| 08.01. | Ocugen, Inc. - 8-K, Current Report | 41 | SEC Filings | ||
| 22.12.23 | Ocugen, Inc. - 8-K, Current Report | 86 | SEC Filings | ||
| 13.12.23 | Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410-Modifier Gene Therapy-for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | 19 | GlobeNewswire (USA) | ||
| 10.11.23 | Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST-Modifier Gene Therapy-for Stargardt Disease | 1.073 | GlobeNewswire (Europe) | MALVERN, Pa., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 4.229 |
| NEL | 4.051 |
| PALANTIR TECHNOLOGIES | 3.614 |
| TUI | 2.806 |
| BAYER | 2.567 |
| INFINEON | 2.416 |
| SIEMENS ENERGY | 2.353 |
| MERCEDES-BENZ | 2.138 |
| DEUTSCHE BANK | 2.131 |
| NVIDIA | 2.080 |
| DEUTSCHE LUFTHANSA | 1.985 |
| BYD | 1.855 |
| VARTA | 1.710 |
| ALLIANZ | 1.647 |
| PLUG POWER | 1.591 |
| RHEINMETALL | 1.525 |
| TESLA | 1.432 |
| AIXTRON SE | 1.427 |
| SUPER MICRO COMPUTER | 1.401 |
| RENK GROUP | 1.395 |
| RWE | 1.385 |
| VOLKSWAGEN | 1.316 |
| COMMERZBANK | 1.295 |
| BASF | 1.228 |
| TEAMVIEWER | 1.089 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
